846557-71-9 Usage
Biochem/physiol Actions
ML385 inihbits the activity of the Nrf2 transcription factor by binding to Neh1, a CNC-bZIP domain that allows Nrf2 to heterodimerize with small Maf proteins, blocking NRF2 transcriptional activity. Much research has been done on activating Nrf2 because it induces cytoprotective antioxidant genes. However, some cancer cells may use Nrf2 similarly for their survival. Nrf2 is overexpressed in certain cancers such as non-small cell lung cancer (NSCLC) often due to loss of function mutations in KEAP1, which targets Nrf2 for proteasomal degradation. ML385 was found to have anti-tumor activity with specificity and selectivity for NSCLC cells with KEAP1 mutations.
Check Digit Verification of cas no
The CAS Registry Mumber 846557-71-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,6,5,5 and 7 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 846557-71:
(8*8)+(7*4)+(6*6)+(5*5)+(4*5)+(3*7)+(2*7)+(1*1)=209
209 % 10 = 9
So 846557-71-9 is a valid CAS Registry Number.
846557-71-9Relevant academic research and scientific papers
NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY
-
Page/Page column 133; 134, (2014/09/29)
Small molecule inhibitors of Nrf2 and methods of their use are provided for treating or preventing a disease, disorder or condition associated with an Nrf2- regulated pathway. The compound can be administered as a single agent or can be administered to enhance the efficacy of a chemotherapeutic drug and/or radiation therapy.
